parkinson‘s disease is one of the most im- the heiligendamm round table portant movement disorders. it affects large numbers of patients. the burden of disease peter riederer - drug treatment of parkinson‘s disease: how it all started is tremendous. nowadays, numerous drugs are available for its symptomatic treatment. Interdisciplinary the backbone of parkinson‘s disease treat- Working Group for ment, however, is the dopamine replacement Movement Disorders therapy. this treatment concept is a brilliant example of a rational drug development based on neu- ropathology, biochemistry and pharmacology. how did this concept emerge? what were the obstacles? how could they be overcome? who was involved? how did this idea spread? Peter Riederer, one of the world experts of clinical neurochemis- try, was there where the dopamine replacement therapy was developed. who could better answer our questions?

Dirk Dressler, MD, PhD Head of Movement Disorders Section Department of , Hannover Medical School Hannover, peter riederer drug treatment of parkinson‘s IAB - Interdisciplinary Working Group for Movement Disorders disease: how it all started Dr. Fereshte Adib Saberi Brahmsallee 21 D-20144 Hamburg, Germany organisation: dirk dressler, MD, PhD peter riederer born in 1942 in königsberg, germany professor riederer grew up in , and graduated in 1968 from technical university vienna with a degree in technical chemistry. after a research stay at nuclear research centre seibersdorf, austria from 1968-1970 he received a doctorate in engineering. from 1971-1986 he was head of clinical at the ludwig-boltzmann institutes of neurochemistry and clinical neurobiology in vienna and - at the same time - he was appointed pro- fessor at technical university vienna. from 1986-2008 he served as head of clinical neurochemistry at the depart- ment of of würzburg university. he published extensively on various aspects of clinical neurochemistry. he is one of the world experts of neuro- chemistry of parkinson‘s disease.